Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial

Author:

Chen Xia1ORCID,Huang Wei1,Wei Dan23,Zhao Ji-Ping4,Zhang Wei5,Ding De-Guang23,Jiao Yang23,Pan Hong-Ling23,Zhang Jia-Jia4,Zhong Feng5,Gao Feng23,Jin Yi-Ting1,Zheng Yi-Wei23,Zhang Yan-Ji1,Huang Qiao678,Zeng Xian-Tao678ORCID,Zhou Zhong-Yu23ORCID

Affiliation:

1. Hubei University of Chinese Medicine, Wuhan, China

2. Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China

3. Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China

4. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

5. The First Hospital of Hunan University of Chinese Medicine, Changsha, China

6. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

7. Center for Evidence-Based and Translational Medicine, Wuhan University, Wuhan, China

8. Department of Evidence-Based Medicine and Clinical Epidemiology, The Second Clinical College, Wuhan University, Wuhan, China

Abstract

Objectives. This study aimed to examine the efficacy and safety of acupoint catgut embedding (ACE) for obesity over a 16-week treatment period using sham stimulation as the control. Methods. A multicenter, randomised, parallel, sham-controlled trial was conducted from February 10, 2017, to May 15, 2018. Men with waistlines ≥85 cm and women with ≥80 cm at three sites were randomised to receive eight sessions (over 16 weeks) of ACE (n = 108) or sham ACE (n = 108) with skin penetration at sham acupoints. The catgut was embedded once every two weeks using two alternating sets of acupoints. The follow-up lasted for an additional 24 weeks. The primary outcome was the percentage waistline reduction from baseline to week 16. Results. We included 216 individuals in the intention-to-treat analysis. At 16 weeks, the rate of waistline reduction was 8.80% (95% confidence interval (CI), 7.93% to 9.66%) in the ACE group and 4.09% (95% CI, 3.18% to 5.00%) in the sham control group, with a between-group difference of 4.71% (95% CI, 3.47% to 5.95%; P  < 0.0001). This difference persisted throughout the entire follow-up period (between-group difference after 24-week additional weeks, 4.94% (95% CI, 3.58% to 6.30%); P  < 0.001). The subgroup analyses of waistline by sex (male/female) revealed treatment effects of 1.93 (95% CI, −0.37 to 4.23, P  = 0.1) in the male group and 3.19 (95% CI, 1.99 to 4.39, P  < 0.001) in the female group. The adverse event analysis suggested that ACE and laboratory tests confirmed the safety of ACE. Discussion. ACE for 16 weeks could decrease the waistline and weight and was safe for the treatment of obesity. Further research is needed to evaluate the long-term efficacy and sex differences. This trial is registered with NCT02936973.

Funder

TCM Industry of State of Administration of Traditional Chinese Medicine of the People’s Republic of China

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3